ƒ ‹ F | Œfia‹ ˙'e›ß• |–M^D‹ ª¤s›p e ƒ¤"G‡ł§i

ƒh^˜ fl¤ ¥ ¿/§ƒ ƒ~ "ƒ £flf–w.. ƒb^˜«~¥ /‹§@¥ ¿/§‹ yƒ flf

˙‹ ª¤s

›p e^ §¡G §O«‹ ›p e

›p e‰ ¸s„¡GNSC92–2320–B–038–044–

ıƒ · ¶¡¡G92 ƒ~08 /°01 / ØØ 93 ƒ~07 /°31 /Ø

ıƒ ‡ ƒ ¡G» O ¥´ ˙/j ˙/"‹

›p e¥ D ø/¡HG– i '//

‡ł§i^ «‹¡G" °†‡ł§i

‡ B † zŁ¡fG¡¥»›p e¥ i / ‰ ¶‹ d,

// ¥` Œ 93 ƒ~11 /°3 /Ø

(key words)

Drug-Drug interactions DDI Rosholm 48.4% 70 3 4.4% DDI Doucet 70 DDI 65 DDI SAS 8.2 anatomical therapeutic coding ATC Drug interaction facts 10.5% 30.3% 15 2-5 20 4.5% significance “1” Cardiac glycosides/High-ceiling diuretics longitudinal 0.9%

Key words: hypertension, elderly, drug-drug interactions, polypharmacy, prevalence, Incidence

Previous studies have reported the risk factors of drug-drug interactions in polypharmacy include elderly and multiple illness. Rosholm reported the prevalence of polypharmacy for the elderly older than 70 years old is 48.4%, that is 3 times of younger people. Among those, 4.4% had polypharmacy and got the risk of potential drug-drug interactions. The most frequent drugs of hopitalization resulted from potential drug interactions were cardiovascular drugs. Up to date, there is no studies of drug-drug interactions in elderly hypertensive patients with polypharmacy. The study purpose is to find the risk of potential drug-drug interactions in the elderly hypertensive patients with polypharmacy.The data sources from the cohort sampling database used to estimate the prevalence of potential drug-drug interactions and hospitalization incidence induced by adverse drug reactions in the elderly hypertensive patients. The data will be analyzed by SAS 8.2. The formulary lists in the database of national health insurance will be classified by anatomical therapeutic coding (ATC), and the external dosage form will be excluded. Based on the classification of drug interaction facts, the potential drug-drug interactions will be classified. We found the prevalence rate of potential DDIs in general prescriptions and hypertensive prescriptions were 10.5% and 30.3%, respectively. Among the potential DDI pairs, 4.5% pairs were categorized as Class ‘1’ clinical significance. The most common potential DDI pairs in the clinical significance ‘1’ category were Cardiac glycosides/High-ceiling diuretics. Although the prevalence and incidence of potential DDIs were not higher than those of western country, we still have to alert for drug safety.

« e ¤ ¥ ¡ G ‟ ƒ £ ‹ † − ƒ † v ‟ ¥ B ƒ n o ' ƒ ƒ ~ H／Ş″C'°flf¡A
ƒ £ ¥ ~ ¡ A ƒ ƒ ~ ／ H ／ ] − ' ƒ X ¤ ƒ h ″ fl e fl f ¡ Ap¡G／ ¯ƒflf¡
‟ ¢ ¡ B Ş ƒ···→» ¥î‟A ƒ fl ¤ ¥ ¿ƒ h ″ˆ«˜¡Aƒ ] ƒ „ † ¥¤^…˜«fb ¥ ‹Ş@¥¿
／Şf MI'°／ æ ¤¥Ł H‟¡ ¢ «e Œ／″fl ¥Fƒ ƒ ~ ‟ƒ／¿£ñ˜ fl¤ ¥ ‹ ^ ł Ş¡C

‹ ª ¤ ¥ ¡Y¥ » ‹ ª ¤¥ ›／″F , Œ″65 • † Ł／W ƒ ~ ／ H‟ƒ W £ ñ˜ fl¤ ¥ ‟¿″› ƒ]fle
−w¡A¥ i fl ‟›P″ … ƒ ¼M œ¥／„ ƒb DDI ‟″^˜ fl ¡ C ª¤Ş″G¥i¥¿¥H« ł´
fi v Ş ¯†B″ƒŁ ‹ ¡ª A ¢Cflf−w／Ş¥¿^˜ƒ ¥ ' °¡C

／ ˜ m•¡Œi ‹ ª s[1] « ¥X¡A¤ JNC VI • ˙ « h ¡^A¥ ¥ŠWƒ¤ƒ ~ ／ H ‟ƒ(SBP/DBP > or = 140/90 mm Hg ' ¿w‟A¥¿› ƒ £^)／ Ş † − ƒ †¤v¡'A¿ 26%¡A／k' ¿ 19%¡F ƒ ƒ ƒ／(Ł 65 • ł)／ Ş ‟ ƒ £ †=[2,3]ƒ¡A¤k' °‟„F33%, ／k' °‟„F41%¡C‟Ł · ` ¥ ¥»¤ →N† ¥¤...—‟″ „ ' x ¶ffi target organ damage¡^A‰ ƒ p／ ƒfM]¡A ‹ ª a／ flƒ¡]／ −h¡ B ƒ − ¶¡°B¥^‟ « ‟ ¿¡«B ‟ ¡F,£ƒ ″ fl ƒ¡A¥ ] ‹ ª／¡»• …¨fi ' °, ffl°fiæ¡F ¨flƒ¯ ¡F' P ƒ ″ flƒ¡F／¿″ ‰／flƒ¯ ¥[4]¡C¥ B ¥ ' £„ „'ƒX ¤ ¤ ¥Ifl e ffl¡ªA ƒ p ¿ } Ş ¿ fl ƒ¡B flg¥ƒ¡A¥Ł H W″ ″ ƒ ª fl Nefl ŠP ‟ ƒ −£w ‟ −'ƒ†ƒ ñ˜ fl¤ ¥ ¿¡A／ ¤ ƒ ƒ／Ł]−'ƒ†ƒ ª ¤ ¥L „x¤ ¢ ¿fl e ffl¡AGƒ Ł ¤ ¥ ¿ƒ h ″ˆ«˜¡A† y ƒ ¤ ˆ¥k ~ ¥ ‹Ş@Şƒ¿MI'°• |／ æ ¤¥Ł H‟[5-7]¡Cfi ‹ ª s[5,6]¡ Ao¥˝… ƒbˆ˜« ~ ¥ ‹Ş@Ş potential drug-drug interactions¡Fpotential DDIs¡^ ／Şf M I ƒ／]l¥ ¿A ‟˜ ¡ Bh›«fl ŁIf／¿ƒ ñ˜ fl¤ ¥ ¿¡]polypharmacy¡^ ¥ŒŁ ł°†B ／Łƒ†… ƒbDDI ‟ ″æ¤ ‹ 27%ƒ 37%[5,7]¡ Œ]ˆ˜« ~ ¥ ‹Ş@¥›Pƒ |／ Şo¥˝†v ‹ø0~2.8%[8-10]¡C‹ ŒŁ,ƒ~ƒ ／ ƒ†／ QU／Hƒ]¤˜¥¿† BŁˆ˜ƒ ƒ ″ '[11]¡C† ø·ƒ |fi ¤ †O¥i› ŞC'¿` ŞK¡C

／ ˜m／wƒ†fh‰gƒ†^ ƒ~»•／ H˜‟«¥ ／ ‹ Ş¥†¿ ‟Ł″Ş¡A ´A／ ƒ ƒ／‟H ″ ^ ‹ ª ¤s[5,8,12-14]¡ARosholm[14] ¥／H† ‟æ† Şi 70 • † Ł／W ƒ／‟Ł″ƒ ñ˜ fl¤ ¥ ¿† v 48.4%¡A 70 • ¥H／U‟″3 ›¿¡A† ø·ƒ ñ˜ fl¤ ¥ ‟¿″ƒ ƒ／ƒH† 4.4% o¥˝… ƒb DDI ‟ ″ Ł¡ADoucet ¥／H[15] † Şi 70 • † Ł／W ƒ ~H¥˝ŏDDI ƒ ƒ |‟ ¡ A˜ ‟«¥H／ ƒ ″ ^˜‟«† ƒ h¡A¤ ƒ,‹ Of V ″fl«˜‟«¡C– ‘¤£‟″DDI ˘Ş ¢¿¤ ƒ,‹ Ofl«,g ″ fl«» ‟¡ŞCƒ £／¿« ' ° ˙ I″¡C″If ¥ « e ／ ¡A／ ˜m／W' | Lwƒ„ ƒ ″ ƒ £– W ƒ ñ˜ fl¤ ¥ ¿ ¥ƒ ŒDDI ‟ ″ ‹ ª s¡C

‹ ª s／Ł‟k¡G¥»^˜« ~ ¥ ‹Ş@Ş¥¿ª s, Œ fi ¤ ‹•C¥H •«O' «O´k／H' … ¸ Œfi¡˝I¥w«e‹ ø20 ,U／H¡^ƒ ›pƒ ƒ ~ ¥ −w£fœ¥˝^˜« ~ ¥ ‹Ş@¥Ş¿† ƒ ／†¸v o¥˝†v¡C' ƒ †¿›p ／ ‟R−N−˜¥¿SAS 8.2 ‟'¡C› ¥ −N †z‹ ª s·`¶¡' ƒ† •«O ¥I／ Ş˜« «~¶ ¡ A£ ¥ h·^ ¡B¥ ‰Ş^ ¡BŞ łJ fl¥•¥／ ¶ ±J¥ ¤ ›ƒ ‹ y ‟ fk‹‹«~¶ ¡A¥Hanatomical therapeutic coding¡ ]ATC¡ ^¤ ¢ ¿ ^˜†z´k^ ¡C¥t... ƒbˆ˜« ~ ¥ ‹Ş@Ş¥æ„ ¡A «h¤ Drug interaction facts fi ／Ş´k^ « ¡C／W›z« Ş„ƒ¤«Æ¡A¥ Ş ¥Xƒ† ¥ £¶ É_¡A／ ‟R¤ Ei† BŁ／ Ş~˜ ¡ B°ŞO¡B¶ É_¡ B˜« «~¶ …˘¡ Bo¥˝… ƒbˆ˜« ¥ ／ ‹ Ş@¥／¿ Ş˜«~ t„ ¡Bƒ,…˘／¿˜Y›«« ¡A¶if ／ ‟Rƒ]／ £ ¥／˘†ƒ ƒ |／ Şo¥˝†v¡C

‹ ª s ‟G¡G／ ‟R' «O´k／H, Œ fifi†w ¡A Œ／″ •« O B／Ł … ƒbˆ˜« ~ ¥ ‹Ş@¥Ş¿† ƒ ‹†œv 10.5%¡Aƒ ¥ 1997 ƒ~11.9%ƒ 2001 ƒ~9.5%¡Aƒ††vƒ~／U› ／Ş` ¶ (Table I)¡C ƒ ‟ ƒ ł Ł BŁ″ … ƒbˆ˜« ~ ¥ ‹Ş@¥Ş¿† ƒ (Table II)¡A` M／]Şe†vƒ~／U› ／Ş` ¶ ¡Aƒ ¥ Ş¡ ‟„F30.3%¡A« œ ／@fl°† BŁ″ ／Ş／T›¿¡C¥t¥HfUƒ~« ‟ ƒ £ ／H..˘／ ‟R¡A« œƒ†40.7%‟″ ‟ ƒ £ƒW• ƒ†... ƒbˆ˜« ~ ¥ ‹Ş@Ş¥ (Table III)¡C›Y ¥H.. ƒbˆ˜« ~ ¥ ‹Ş@Ş¥„ ...˘／ ‟R¡A«h¤ Ei ‟ ƒ £ BŁ‹ œƒ†0.5 › … ł¥

ㄑ ‹ § @ ¥ (Table IV)¡ C `'1997 ƒ 2001 ƒ ~ ㄑ § " ƒ £ ł B ㄑ Ł "R–o" ¡A¶
§ … ˘ • U ƒ h ㄑ § ł BŁ¡Aƒ§¥ˇ§o¥ ƒ M I ' ° • U " ¡ ¶}łŁ §…˘ㄑj'
"″ł BŁ ł, …˘‹ ø ¶ } ㄑ Ł§2–5 §"″20 ›¿(Table V)¡C¥ ㄑ "R〳– o " Ą "ƒ
£ Ð〳Ł… ƒbˆ ˜¥ ㄑ ‹ §¥‹øƒł4.5%ƒC‹ ` { § ~ ¥«« »§significance
"1"(Table VI)¡C æ ß ƒƒ~ H » ÐDƒ~H " ƒ £ Ð〳§Ł§§P!.˚ƒbˆ ˜¥ ㄑ §@
¥ˇ ` { § ›¤n'˚fi ł§¡A † C§ƒ¡ł¯ ª fit(Table VII)¡ Ą~˜ • U ㄑ j ¡ A ł BŁ〳§… ƒb
ˆ ˜¥ ㄑ ‹ §¥ˇæ¤ • U "¡A { § ›¤n'˚〳]•U¯ ¥«(Table VIII)¡C¥ ` { § ›¤n'˚
´ Ř ‹ ¡§l¡¤〳 § ㄑ ‹ § @ ¥ ł„ Ř¡Ą – ¤£〳§ ł, ‹ Cardiac glycosides/
High-ceiling diuretics(Table IX)¡C
¥ t – N , Œ˜ löwgitudinal〳 " R ¡ Ao23,925〳H¤ªƒ ł ¥ ¶ Œ_¡A¤ 〳ƒł
12,278〳H›–` {… ƒbˆ ˜¥ ㄑ ‹ §¥ˇ¡C23925ƒW " ƒ fŁ Łwˇƒłł318〳Hƒ , ƒ ¶E
´_§tˆ ˜〳 £ ¤ ›ˇ〳§¶ Œ_¡A¤ 〳216〳Hƒ,〳J |¥D¶ Œ_‹ ˆ ˜〳 £ ¤ ›ˇ(¤ł〳
11〳Hƒł¤ ƒ,〳J |)¡A‹ Œ]ˆ ˜〳 £ ¤ ›ˇƒ ł |〳§ o ¥ł‹v 0.9%¡C

Q ‰ ¡ G ` M¥»¶‹G¡Ąs Œ〳 ” L ‰‹Ð–Ø¶¶¡˚ " ƒ £ ł BŁˆ¡Ą˜¥ƒb‹ §¥ˇ
〳§t ƒ ł‹v' ˛ o ¥ˇł¡vĄ§¡¥… " 〳 ˜m〳 §˘ ¡Cƒ ¥ ¶G– o " " ƒ £ł B〳Ł〳§…
ƒbˆ ˜¥ ㄑ ‹ §¥ˇł˛ ƒ ł‹v‹ ø 〳 §˚ł B Ł〳§§T›¿¡A¥ BH ƒ˜ • U "¡Ą ƒ ł‹v•U
"¡C‹G` $ 〳W ł¥ ł jƒ ƒ ~ ¶ fl Œ˘w〳§¥ˇ^˜– ¤|¡A ł¥ „ ¶£' ´ fiv¶ ›Ł fi
· ¥ ›«›n〳 § ㄑ ‹ § @ ¥ ł Ą„› §Cƒ]ˆ ˜¥ ㄑ ‹ §¥ˇ˛ _〳§〳 £ ¤ ›ˇ¡C M¥»
‹ ªs ¶G¥ i , ˜ ł•«Ø Łˆ˜〳 § …ƒbˆ ˜¥ ㄑ ‹ §¥ˇł ¶p¡Aƒ ł\ƒh¥ ł ł¥˝flffi
ƒł` ˚ ¶ƒ¤˜'˛«Dł B Ł〳§〳?˜ƒ ƒ"¥Ą˛¡Ał ø·^ ˜〳~ƒ] «O〳£ ¥I¡A‹G «O,Œ
fi fiw L " k£¤ ^ Tfi§Ą' ¥ H ¥‹ ª¶s¥ i fl § C ƒ ¥ .«ebŒ〳˜¥ 〳‹
§ Ø˛〳§t ¶p¡C

« ˜ ł G¡¥ »łł ƶL„ ´ ¤˘〳H›ß〳§« ø ˜ ––¤Ą¥ [ – j ´fiv˜fiy^ ˜¥ ㄑ ‹ §¥ˇ〳§›«›n
' ¡Aƒ ` $ 〳W ¥ ¶•¥˛〳§ˆ ˜〳~¡A ł" ` • N ‰ ªA¡Ł¶§Kƒ]¥ 〳 ‹ §¥ˇ˛ Ø˝〳§
ƒ MI¡C„ ¥ ł ł〳]¥ † ¶ • ł z „ L ˙ fi —¤¡Ą–˛–C¤Ø¦¶¥…‰ † ł H•N¶¥if "A
fl Ø˝〳 § M¡C

ƒ ⁄˜m¡G
1. Pan WH, Chang HY, Yeh WT, Hsiao SY, Hung YT. Prevalence, awareness, treatment and control of hypertension in Taiwan: results of Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996. J Hum Hypertens 2001;15:793-8.
2. Liau CS, Tseng YZ, Lee TK. Prevalence of cardiovascular diseases in elderly Chinese people in Taiwan. Int J Cardiol 1998;67:177-81.
3. Tseng WP. Epidemiology of hypertension among Chinese in Taiwan. J Hum Hypertens 1990;4:144-6.
4. NM K. Kaplan's Clinical hypertension. 8 ed: Wolters Kluwer; 2002.
5. Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991;8:234-6.
6. Cadieux RJ. Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med 1989;86:179-86.
7. Mok H, Mulpeter K, O'Connor P, Feely J. Drug-drug interactions in hospital. Ir Med J 1991;84:26.
8. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993;9:51-9.
9. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832-40.
10. Merlo J, Liedholm H, Lindblad U et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. Bmj 2001; 323:427-8.
11. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 1998;279:1200-5.
12. Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992;21:294-300.
13. Tamai IY, Strome LS, Marshall CE, Mooradian AD. Analysis of drug-drug interactions among nursing home residents. Am J Hosp Pharm 1989;46:1567-9.
14. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull 1998;45:210-3.
15. Doucet J, Chassagne P, Trivalle C et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996;44:944-8.

Table I ¡X 1997 ƒ ƒ 2001 ƒ~^ ˜ « ~ ‡ ⁄ Ł ‡ B ⁄ Ł ⁄ § … ƒ b ^ ˜ « ~ ¥⁄‹ §@¥ ¸⁄§‡B⁄Ł†

| | ' ƒ ‡ B⁄Ł‡…˘ | ⁄ Ł B⁄Ł…˘ | DDI ‡ …˘ | DDI ‡ B Ł…˘ | DDI ‡ BŁ⁄ æ (%)* |
|---|---|---|---|---|---|
| 1997 | 1,239,904 | 1,190,591 | 213,420 | 141,778 | 11.9 |
| 1998 | 1,546,594 | 1,488,499 | 263,798 | 173,790 | 11.7 |
| 1999 | 2,066,431 | 1,985,219 | 309,912 | 208,400 | 10.5 |
| 2000 | 1,980,904 | 1,897,676 | 267,647 | 182,092 | 9.6 |
| 2001 | 1,976,130 | 1,885,932 | 261,600 | 178,256 | 9.5 |
| Total | 8,809,963 | 8,447,917 | 1,316,377 | 884,316 | 10.5 |

*DDI ‡ BŁ⁄ æ = DDI ‡ B Ł…/‡ ⁄ Ł B⁄Ł…˘

Table II ¡X 1997 ƒ ƒ 2001 ƒ~ " ƒ ‡£ B ⁄ Ł ⁄ § … ƒ b ^ ˜ « ~ ¥ ⁄ ‹ §¥ ¸⁄§‡B⁄Ł†−ƒ †v

| Total | " ƒ £ ‡ B Ł…˘ | DDI ‡ …˘ | DDI ‡ B Ł…˘ | DDI ‡ BŁ⁄ æ (%)* |
|---|---|---|---|---|
| 1997 | 45,591 | 25,813 | 15,364 | 33.7 |
| 1998 | 61,682 | 32,808 | 20,010 | 32.4 |
| 1999 | 95,350 | 48,503 | 29,465 | 30.9 |
| 2000 | 111,416 | 53,002 | 32,417 | 29.1 |
| 2001 | 122,730 | 55,341 | 35,186 | 28.7 |
| Total | 436,769 | 215,467 | 132,442 | 30.3 |

*DDI ‡ B ⁄ Łæ¤= DDI ‡ BŁ…˘/ " ƒ ‡£ BŁ…˘

Table III ¡X1997 ƒ ƒ 2001 ƒ~ " ƒ ‡£ f − w … ƒ b ^ ˜ « ~ ¥ ⁄ §(¥¥H¸†−ƒH ‹†)⁄ƒ "R

| | ‡ ⁄ Ł B⁄Ł˘ | ‡ BŁ ` ⁄H…˘ | " ƒ £ ⁄H…˘ | " ƒ ‡£ f w ƒ‡DDI ⁄H…˘ | " ƒ ‡£ f w ¥˝ potential DDI ⁄ æ (%) |
|---|---|---|---|---|---|
| 1997 | 1,190,591 | 135,038 | 7,627 | 3,284 | 43.1 |
| 1998 | 1,488,499 | 148,572 | 10,142 | 4,212 | 41.5 |
| 1999 | 1,985,219 | 161,075 | 12,992 | 5,465 | 42.1 |
| 2000 | 1,897,676 | 162,988 | 14,942 | 5,920 | 40.0 |
| 2001 | 1,885,932 | 162,868 | 15,728 | 6,142 | 39.0 |
| Total | 8,447,917 | 770,541 | 61,431 | 25,023 | 40.7 |

Table IV ¡X1997 ƒ ƒ 2001 ƒ~ " ƒ ‡£ f − w … ƒ b ^ ˜« ~¥ ⁄ ¤ ⁄ ¤ ¥ ¸§ t„† − ƒ †v⁄ "R

| | ‡ ⁄ Ł B⁄Ł˘ | ‡ BŁ ` ⁄H…˘ | " ƒ £ ‡ BŁ…˘ | " ƒ ‡£ BŁ DDI ‡ …˘ | ¤ ⁄ ¤ ¥ ¸§ t potential DDI ‡ …˘ |
|---|---|---|---|---|---|
| 1997 | 1,190,591 | 135,038 | 45,591 | 25,813 | 0.57 |
| 1998 | 1,488,499 | 148,572 | 61,682 | 32,808 | 0.53 |
| 1999 | 1,985,219 | 161,075 | 95,350 | 48,503 | 0.51 |
| 2000 | 1,897,676 | 162,988 | 111,416 | 53,002 | 0.48 |
| 2001 | 1,885,932 | 162,868 | 122,730 | 55,341 | 0.45 |
| Total | 8,447,917 | 770,541 | 436,769 | 215,467 | 0.49 |

Table V¡ X ‟ ƒ £ ǂ B ⁄ Ł ⁄ § ˆ ˜ « ~ § … ˇ » P … ƒ ƀ˜«~¥ ⁄‹§@¥¸⁄§‹ „ ƒM

| ¶ } ⁄ Ł§…ˇ ‟ ƒ £ /ǂ ɃŁ | Potential ǂ B Ł…ˇDDI | Potential ǂ B Ł…ˇDDI | ¤ ∈i ‟ ƒ £ǂB ⁄Ł§t DDI t„ …ˇ | potential ‹ „ ℳ I'° |
|---|---|---|---|---|
| 1 § | 47724 | 0 | 0 | 0 | ¡X |
| 2-5 § | 300305 | 77962 | 101253 | 0.3 | 1 |
| 6-10 § | 86350 | 52367 | 106103 | 1.2 | 4 |
| 11-15 § | 2324 | 2047 | 8265 | 3.6 | 12 |
| >15 § | 66 | 65 | 398 | 6 | 20 |
| Total | 436769 | 132441 | 216019 | 0.5 | 1.7 |

Table VI¡ X ‟ ƒ £ǂɃ.⁄Ł ƒ b ˆ ˜ « ~ ¥⁄‹§[@§¸⁄⊗›ℌ æß

| Significance | No. of potential DDI | Percentage (%) |
|---|---|---|
| 1 | 9827 | 4.5 |
| 2 | 39751 | 18.4 |
| 3 | 16746 | 7.8 |
| 4 | 109520 | 50.7 |
| 5 | 40175 | 18.6 |
| Total | 216019 | 100 |

Table VII¡ X ‟ ƒ £ ǂ B ⁄ Ł ƒ ƒ ~ ⁄ H » P « D ƒ ƒ ~ ⁄ H ⁄ § ' ° § ⊗P… ƒbˆ˜«~¥

| | ⁄ j ' ¥65 • ǂ⁄§ ‟ ƒ £ǂB⁄Ł (N=232,880) | | ⁄p' 65 • ǂ⁄§ ‟ ƒ £ǂB⁄Ł (N=203,889) | | P value |
|---|---|---|---|---|---|
| | N | % | N | % | |
| Sex | 232880 | 53.32 | 203889 | 46.68 | <0.0001 |
| M | 117490 | 26.90 | 96153 | 22.01 | |
| F | 115311 | 26.40 | 107568 | 24.63 | |
| Unknown | 79 | 0.02 | 168 | 0.04 | |
| DDI significance | 129934 | 60.15 | 86085 | 39.85 | <0.0001 |
| 1 | 6533 | 3.02 | 3294 | 1.52 | |
| 2 | 23553 | 10.90 | 16198 | 7.50 | |
| 3 | 10841 | 5.02 | 5905 | 2.73 | |
| 4 | 63624 | 29.45 | 45896 | 21.25 | |
| 5 | 25383 | 11.75 | 14792 | 6.85 | |

Table VIII¡ X ‟ ƒ £ ∔ B ⁄ Ł ⁄ ⁄ … ƒ b ˆ ˜ « ~ ¥ ⁄ §@¥¸`{§ ›« ›n'°⁄§

| | Age | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | <31 N (%) | 31-40 N (%) | 41-50 N (%) | 51-60 N (%) | 61-70 N (%) | 71-80 N (%) | >80 N (%) | Total N (%) |
| Total hypertensive prescriptions | 2496 | 11944 | 53657 | 87477 | 135838 | 116097 | 29260 | 436769 |
| Pairs of potential DDI / Ratings of Potential DDI | 841 (33.6) | 4524 (37.7) | 19308 (36.1) | 37031 (42.4) | 69232 (50.9) | 67921 (58.5) | 17162 (58.7) | 216019 (49.4) |
| 1 | 28 (1.1) | 159 (1.3) | 661 (1.2) | 1297 (1.5) | 3038 (2.2) | 3306 (2.8) | 1338 (4.6) | 9827 (2.2) |
| 2 | 258 (10.3) | 931 (7.8) | 3624 (6.7) | 6909 (7.9) | 13011 (9.6) | 12555 (10.8) | 2463 (8.4) | 39751 (9.1) |
| 3 | 80 (3.2) | 313 (2.6) | 1360 (2.5) | 2521 (2.9) | 4982 (3.7) | 5758 (5.0) | 1732 (5.9) | 16746 (3.8) |
| 4 | 337 (13.5) | 2400 (20.0) | 10586 (20.0) | 19588 (22.4) | 35910 (26.4) | 32869 (28.3) | 7830 (26.8) | 109520 (25.1) |
| 5 | 138 (5.5) | 721 (6.0) | 3077 (5.7) | 6716 (7.7) | 12291 (9.0) | 13433 (11.6) | 3799 (13.0) | 40175 (9.2) |

Table IX¡ X ‟ ƒ £ ∔ B ⁄ Ł ´ ‰ “‹l”›{§ «›« ›n ¶ W t„

| Coprescribed drug pairs | | No. of pairs (Total=9827) | Percentage (%) |
|---|---|---|---|
| Cardiac glycosides | High-ceiling diuretics | 3247 | 33.04 |
| Beta blocking agents | Selective calcium channel blockers with direct cardiac effects | 1342 | 13.66 |
| Cardiac glycosides | Low-ceiling diuretics, thiazides | 879 | 8.94 |
| Potassium sparing agents | ACE inhibitors | 675 | 6.87 |
| Cardiac glycosides | Low-ceiling diuretics, excl. thiazides | 477 | 4.85 |
| Propulsives | High-ceiling diuretics | 329 | 3.35 |
| Cardiac glycosides | Antiarrhythmics, class I and III | 323 | 3.29 |
| Cardiac glycosides | Selective calcium channel blockers with direct cardiac effects | 303 | 3.08 |
| Antithrombotic agents | Antithrombotic agents | 212 | 2.16 |
| Antithrombotic agents | Antiarrhythmics, class I and III | 212 | 2.16 |
| Others | | 1828 | 18.60 |